- Home
- BLRX vs NCEL Comparison
BLRX vs NCEL Comparison
Compare BLRX & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLRX | NCEL |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | Israel | Switzerland |
| Employees | N/A | 11 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 13.2M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | BLRX | NCEL |
|---|---|---|
| Price | $2.33 | $2.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | 13.2K | ★ 16.3K |
| Earning Date | 03-23-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.28 | $1.89 |
| 52 Week High | $7.77 | $4.70 |
Technical Indicators
Market Signals| Indicator | BLRX | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.88 | 32.79 |
| Support Level | N/A | $1.89 |
| Resistance Level | $2.76 | $3.16 |
| Average True Range (ATR) | 0.18 | 0.15 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 52.06 | 3.91 |
Price Performance
Historical ComparisonAbout BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.